Plasma Cell Dyscrasia Panel Discussion

 Dr. Peter Anglin, Dr. Christine Chen, Dr. Tony Reiman

About Speakers

Dr. Peter Anglin

Dr. Peter Anglin – Stronach Regional Cancer Centre

Dr. Peter Anglin obtained his medical degree from Queen’s University at Kingston and followed this with clinical fellowships in internal medicine, hematology and oncology. He has been in clinical practice for the last 21 years in the Greater Toronto Area and is currently a staff Hematologist/Medical Oncologist and Physician Lead at the Stronach Regional Cancer Centre at Southlake Health in Newmarket, Ontario. Dr. Anglin’s clinical focus has been in hematologic and lymphoid malignancies. After pursuing an MBA from the Rotman School of Management (University of Toronto) he has developed an interest in health systems delivery and process redesign in the clinical ambulatory setting.

Dr. Christine Chen

Dr. Christine Chen – Princess Margaret Cancer Centre 

Dr. Christine Chen is the Medical Director of the Autologous Stem Cell Transplant Program and Clinical Lead for the Immune Effector Cell (IEC) Therapy Program at the Princess Margaret Cancer Centre, University Health Network (UHN), in Toronto, Canada.  She is appointed as an Associate Professor at the University of Toronto (U of T) and is a member of the clinical research group for multiple myeloma and related mature B-cell disorders, including chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM).  Princess Margaret Cancer Centre is the largest tertiary care center for cancer in Canada, performing over 300 autologous stem cell transplants and seeing over 400 new referrals for myeloma, CLL and WM per year.  As Clinical Lead for the IEC Program, Dr. Chen led the implementation of CAR T-cell therapy at PM, one of only 6 centres in Canada certified to perform this complex, innovative therapy.  As a clinical investigator, Dr. Chen’s research interests are in the development of novel approaches for myeloma and CLL, focusing on cell-based therapy. Dr. Chen also holds the role of Quality Director for the Princess Margaret BMT-IEC Quality Program providing oversight for both standard of care and research cell therapy processes and maintaining FACT (Foundation for the Accreditation of Cellular Therapy) accreditation.

Dr. Tony Reiman

Dr. Tony Reiman – Beatrice Hunter Cancer Research Institute

Dr. Tony Reiman is a medical oncologist at the Saint John Regional Hospital in New Brunswick, a Professor of Medicine at Dalhousie University, and the Canadian Cancer Society Research Chair at the University of New Brunswick. He has a clinical and research interest in biomarkers and novel therapies for multiple myeloma. Dr. Reiman is a hematology and myeloma co-chair with the Canadian Cancer Trials Group. He is a member of the International Myeloma Working Group and the US NCI Myeloma Steering Committee. He is a member of the Board of Directors of Myeloma Canada and is the Atlantic Node Leader of the Terry Fox Research Institute. His research is funded by CIHR, TFRI, CCS, NBHRF, BHCRI and industry partners

Thank you to our WHU 2021 Sponsors